NEW YORK (GenomeWeb News) – A new company called Oxford Cancer Biomarkers has been formed to provide oncology consulting services and new cancer biomarkers.
The company, which is headquartered in Oxford and Reading, UK, is developing new biomarkers using CancerNav, a DNA- and protein-based assay technology platform developed by Nick La Thangue, chair of cancer biology at Oxford University, and David Kerr, professor of cancer medicine at the university.
Quintiles is the largest shareholder in Oxford Cancer Biomarkers. La Thangue, Kerr, and the University of Oxford are the other major shareholders.
Oxford Cancer Biomarkers has a strategic relationship with Quintiles Consulting and Quintiles Global Laboratories, which Quintiles said has the "capabilities and expertise to operationalize the consulting and biomarker R&D innovations" from Oxford Cancer Biomarkers for use by global biopharm companies.